KLK5-INHIBITING PEPTIDE Russian patent published in 2024 - IPC C07K16/00 C07K14/81 C07K19/00 C12N15/12 C12N15/63 G01N33/15 G01N33/53 A61K45/00 A61K48/00 A61K35/12 A61K47/65 A61P35/00 A61P25/00 A61P17/00 A61P17/06 

FIELD: biotechnology.

SUBSTANCE: mutant SPINK2 peptide is provided, which inhibits the protease activity of active human KLK5, and wherein said peptide comprises certain amino acid sequences, a polynucleotide for producing the mutant SPINK2 peptide, a vector for producing the mutant SPINK2 peptide, a cell for producing the mutant SPINK2 peptide, which contains a polynucleotide or a vector, methods of producing the mutant SPINK2 peptide, conjugates for inhibiting protease activity of human KLK5 and methods for preparing them, compositions and pharmaceutical compositions for treating and prevention of a disease associated with KLK5 and use thereof, as well as methods of treating or preventing a disease associated with KLK5. Also described are compositions for testing and for diagnosing diseases associated with KLK5, KLK5 expression, KLK7 expression and/or KLK14 expression, a method for identifying a mutant SPINK2 peptide inhibiting KLK5, wherein said peptide contains an amino acid sequence presented in SEQ ID NO: 61, methods for identifying a KLK5-inhibiting compound, a method for assessing KLK5 protease activity, KLK5-inhibiting mutant SPINK2 peptides.

EFFECT: invention is used to treat a disease in a subject associated with KLK5, in particular, where the disease is Netherton syndrome, atopic dermatitis, rosacea, UV-induced skin damage, psoriasis, asthma, spinal cord injury, cancer or Barrett's esophagitis.

69 cl, 7 tbl, 107 dwg, 7 ex